Zimmer Biomet Holdings, Inc. (NYSE:ZBH) is trading up 29.89% versus 12-month low of 87.52 and stands -14.47% lower from its 1-year peak of $132.90. The consensus price target (PT) of $130.10 means that the market expects Company shares to increase by 21.6% in the short run. The sell-side target prices range from $100 to $155. In the last month the stock has moved in price 9.08%, with a one year change of 14.88%. The last trading session volume compares with the 1.96M average and market worth floats around 22.77B.
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) gained 6.23% to reach at the trading price of $113.67 as it is set to release its next quarterly earnings report on February 02, 2017. Zimmer Biomet Holdings, Inc. stock trades in the range of $110.50 to $115.94 before the earnings release. Let’s take a closer look at the current earnings forecast, particularly the things traders should pay close attention to. Earnings per share for the recently concluded quarter is expected to come in at $2.11 a share with $1.97B in revenue.
Zimmer Biomet Holdings, Inc. (ZBH) Future Earnings & History
After upcoming fiscal quarter results, all eyes will be on the prospects for the next reporting quarter. Analysts, on average, forecast Zimmer Biomet Holdings, Inc. to earn $2.15 per share (EPS) on revenue of $1.99B. The EPS consensus range is $2.07-$2.29 on revenue between $2.02B and $1.96B.
While if we look at the Earnings Track Record, Zimmer Biomet Holdings, Inc. (ZBH) managed to surpass quarterly earnings per share estimates in 11 of the trailing twelve fiscal quarters, and has a positive trend with an average surprise of 91%. Last time the company reported, Zimmer Biomet Holdings, Inc. (ZBH) generated $1.79 in earnings per share, beating the consensus estimate of $1.79. Revenues hit $1.83B in the September 2017 quarter, which was below the consensus $1.84B projection. On the other hand, in the June 2017 quarter the company recorded a net $1.93B revenue with earnings per share of $2.02. Wall Street had anticipated $1.9B and $1.97, respectively. For comparison, there was a revenue of $1.9B and EPS of $2.00 in the March 2016 period.
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Analyst Insights
The buoyancy in the outlook of Zimmer Biomet Holdings, Inc. (ZBH) is getting stronger by the somewhat negative sentiment (2.00 on a 5-point scale) that sell-side analysts have provided concerning it. Brokerage firms on the average advocate the company shares as Sell. Needham has been covering shares of ZBH, so it is most recent view is worth a look. In a research note issued on Nov 29, 2016, analysts at Citigroup lifted the stock to Neutral from Sell. Another noteworthy analyst activity was recorded on Nov 01, 2016. Needham Analysts lifted the stock to Strong Buy from Buy.